AI-generated analysis. Always verify with the original filing.
Immuneering Corporation announced Q4 and full-year 2025 financial results, reporting 64% overall survival at 12 months in its Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, cash of $217 million extending runway into 2029, and alignment with FDA/EMA on Phase 3 trial design with first patient dosing mid-2026.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang
. Financial Statements and Exhibits. (d) Exhibits The following exhibits relate to Item 2.02, which shall be deemed to be furnished, and not filed: Exhibit No.